Abstract
Gelatinase B/MMP-9 fulfills crucial regulator or effector functions in disease states and may be pharmacologically targeted by specific inhibitors. The characteristics of cleavages of a natural gelatinase B substrate were simulated and amino acids with zinc-ion chelating side-groups were employed to design a library of peptide-based inhibitors. Here, we extend previous findings of combinatorial chemical synthesis and subsequent library deconvolution with a recently established high-throughput technology. This enabled us to study MMP inhibitors with two zinc-binding groups and to identify a new L-pyridylalanine-containing gelatinase B inhibitor. The peptide analog was found to inhibit, almost to the same degree, the neutrophil enzymes collagenase 2/ MMP-8 and MMP-9 and the monocytic tumor necrosis factor-β (TNF-β) converting enzyme (TACE/ADAM-17) in vitro and to protect mice against lethal endotoxinemia in vivo. These data illustrate the usefulness of the screening platform for protective inhibitor discovery and complement recent insights in the pathogenesis and treatment of shock syndromes.
Keywords: Matrix metalloproteinase, lipopolysaccharide, sepsis, inflammation, neutrophil, endotoxin
Combinatorial Chemistry & High Throughput Screening
Title: Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library
Volume: 9 Issue: 8
Author(s): Christiane Dillen, Pierre Fiten, Patrick Chaltin, Jialiang Hu, Veronique Dubois, Philippe E. Van den Steen and Ghislain Opdenakker
Affiliation:
Keywords: Matrix metalloproteinase, lipopolysaccharide, sepsis, inflammation, neutrophil, endotoxin
Abstract: Gelatinase B/MMP-9 fulfills crucial regulator or effector functions in disease states and may be pharmacologically targeted by specific inhibitors. The characteristics of cleavages of a natural gelatinase B substrate were simulated and amino acids with zinc-ion chelating side-groups were employed to design a library of peptide-based inhibitors. Here, we extend previous findings of combinatorial chemical synthesis and subsequent library deconvolution with a recently established high-throughput technology. This enabled us to study MMP inhibitors with two zinc-binding groups and to identify a new L-pyridylalanine-containing gelatinase B inhibitor. The peptide analog was found to inhibit, almost to the same degree, the neutrophil enzymes collagenase 2/ MMP-8 and MMP-9 and the monocytic tumor necrosis factor-β (TNF-β) converting enzyme (TACE/ADAM-17) in vitro and to protect mice against lethal endotoxinemia in vivo. These data illustrate the usefulness of the screening platform for protective inhibitor discovery and complement recent insights in the pathogenesis and treatment of shock syndromes.
Export Options
About this article
Cite this article as:
Dillen Christiane, Fiten Pierre, Chaltin Patrick, Hu Jialiang, Dubois Veronique, Van den Steen E. Philippe and Opdenakker Ghislain, Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library, Combinatorial Chemistry & High Throughput Screening 2006; 9 (8) . https://dx.doi.org/10.2174/138620706778249758
DOI https://dx.doi.org/10.2174/138620706778249758 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment
Combinatorial Chemistry & High Throughput Screening How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Serotonin2C Receptors and the Motor Control of Oral Activity
Current Neuropharmacology The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Effects of ACE Inhibitors on Skeletal Muscle
Current Pharmaceutical Design Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Age-Dependent Biochemical Dysfunction in Skeletal Muscle of Triple- Transgenic Mouse Model of Alzheimer`s Disease
Current Alzheimer Research Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Cyclopeptides from Marine Organisms
Mini-Reviews in Organic Chemistry Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Use of Human Umbilical Cord Blood (HUCB) Cells to Repair the Damaged Brain
Current Neurovascular Research The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Novel Nanotechnology Strategies in Plant Biotransformation: A Contemporary Overview
Recent Patents on Biotechnology Mesothelioma - Update on Management
Current Respiratory Medicine Reviews Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets